BioNTech (NASDAQ:BNTX) CEO Sells $4,633,120.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 46,000 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00. Following the completion of the sale, the chief executive officer owned 410,209 shares in the company, valued at approximately $41,316,250.48. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.

BioNTech Stock Up 0.8%

BNTX opened at $99.26 on Friday. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a market cap of $25.10 billion, a PE ratio of -12.68 and a beta of 1.29. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $98.03 and a 200 day moving average of $94.76.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.60) EPS. On average, sell-side analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. Monaco Asset Management SAM bought a new position in shares of BioNTech during the fourth quarter valued at about $1,594,000. Hsbc Holdings PLC bought a new stake in shares of BioNTech in the 4th quarter valued at about $4,969,000. Bank of America Corp DE lifted its stake in shares of BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after acquiring an additional 474,796 shares during the period. Finally, Amundi boosted its holdings in BioNTech by 24.5% during the 1st quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after acquiring an additional 25,506 shares during the period. 15.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on BNTX. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a report on Monday, June 1st. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. UBS Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.